CAMP4 Therapeutics Corporation (CAMP) Stock Price & Growth Analysis

Quote Panel

Updated March 11, 2025

1W -13.25 % 1M -6.26 % 3M -52.82 % 1Y 38.28 %

Key Metrics

Market Cap
84.47M
Shares Outstanding
20.16M
Share in Float
2.64M
Dividende
0

Earning Date
13 Mar 2025
Price Target
4.19
Average Volume
79037
Beta
-6.996122

Range
3.5-12.3
Industry
Biotechnology
Website
https://www.camp4tx.com/
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.45x

P/S Ratio

10.84x

P/B Ratio

16.8

Debt/Equity

-50.1%

Net Margin

$-2.6

EPS

How CAMP compares to sector?

P/E Ratio

Fundamentals

Relative Strength

CAMP

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

CAMP

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$229M

327%

2024-Revenue

$2.10

2024-EPS

$12M

809%

2024-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

William Blair

initialise

Previous: Not converted

2024-11-05

Now: Outperform

Leerink Partners

initialise

Previous: Not converted

2024-11-05

Now: Outperform

Piper Sandler

initialise

Previous: Not converted

2024-11-05

Now: Overweight

Raymond James

upgrade

Previous: Not converted

2023-06-26

Now: Buy

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.22

N/A

-0.23
vs 3.22

Q2.22

N/A

-2.30
vs 1.84

Q3.22

N/A

-0.46
vs 1.84

Q4.22

N/A

-0.06
vs -1.84

Q1.23

+700%

1.38
vs -0.23

Q2.23

N/A

-0.23
vs -2.30

Q3.23

N/A

-0.01
vs -0.46

Q4.23

N/A

-3.91
vs -0.06

Q1.24

N/A

-2.04
vs 1.38

Q2.24

N/A

-0.92
vs -0.23

Sales Growth

YoY

Current

Estimates

Q1.22

-17%

68.4M vs 81.9M

Q2.22

-19%

64.7M vs 79.7M

Q3.22

-8%

72.8M vs 79M

Q4.22

+15%

78.9M vs 68.8M

Q1.23

+15%

78.5M vs 68.4M

Q2.23

+10%

70.9M vs 64.7M

Q3.23

-15%

61.7M vs 72.8M

Q4.23

-32%

53.6M vs 78.9M

Q1.24

-35%

51.3M vs 78.5M

Q2.24

-24%

54M vs 70.9M

Return on Equity

QoQ

Q1.22

-12%

-0.12
vs -0.14

Q2.22

-43%

-0.43
vs -0.12

Q3.22

-34%

-0.34
vs -0.43

Q4.22

-25%

-0.25
vs -0.34

Q1.23

-57%

-0.57
vs -0.25

Q2.23

-32%

-0.32
vs -0.57

Q3.23

-40%

-0.40
vs -0.32

Q4.23

+115%

1.15
vs -0.40

Institutionnal Ownership

QoQ

Q3.22

101

101
vs 101

Q4.22

98
vs 101

-3%

Q1.23

88
vs 98

-10%

Q2.23

71
vs 88

-19%

Q3.23

58
vs 71

-18%

Q4.23

49
vs 58

-16%

Q1.24

1
vs 49

-98%

Q2.24

1
vs 1

Earnings Growth

Forecast

$229M

327%

2024-Revenue

$2.10

2024-EPS

$12M

809%

2024-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

William Blair

initialise

Previous: Not converted

2024-11-05

Now: Outperform

Leerink Partners

initialise

Previous: Not converted

2024-11-05

Now: Outperform

Piper Sandler

initialise

Previous: Not converted

2024-11-05

Now: Overweight

Raymond James

upgrade

Previous: Not converted

2023-06-26

Now: Buy

Company Description

5.10USD

N/A

0.45x

10.84x

16.8

-50.1%

$-2.6

$229M

$2.10

$12M

Earnings Growth

Latest News

Latest News

Latest News

N/A

0.45x

10.84x

16.8

-50.1%

$-2.6

$229M

$2.10

$12M